Soluble guanylate cyclase stimulation: An emerging option in pulmonary hypertension therapy

European Respiratory Review

Volumn 18, Issue 111, 2009, Pages 35-41

  Ghofrani, H A ^a   Grimminger, F ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Haemodynamics; Pulmonary hypertension; Riociguat

Indexed keywords

BAY 63 2521; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE; RIOCIGUAT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; FLUSHING; GAS EXCHANGE; HEADACHE; HEART PALPITATION; HEMODYNAMICS; HOT FLUSH; HUMAN; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PROGNOSIS; PULMONARY HYPERTENSION; SIDE EFFECT; SIGNAL TRANSDUCTION; VASODILATATION;

ENZYME ACTIVATION; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; PYRAZOLES; PYRIMIDINES; VASODILATOR AGENTS;

EID: 61649094752     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00011112     Document Type: Article

References (48)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
2. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′- cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-3207.
3. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
5. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo- controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109: 750-755.
6. Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS. Intensive Care Med 1990; 16: 227-232.
7. Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32:619-628.
8. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
9. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.
10. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
11. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006; 129: 417-425.
12. Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000; 36: 2204-2211.
13. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618-628.
14. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62: 1759-1764.
15. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004; 109: 3106-3111.
16. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
17. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
18. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
19. Michelakis ED. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003; 8: 5-21.
20. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-2265.
21. Kamisaki Y, Saheki S, Nakane M, et al. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 1986; 261: 7236-7241.
22. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP, 1983; 9: 281-296.
23. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circulation 2003; 108: 2172-2183.
24. Warner TD, Mitchell JA, Sheng H, Murad F. Effects of cyclic GMP on smooth muscle relaxation. Adv Pharmacol 1994; 26: 171-194.
25. Li D, Laubach VE, Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 2001; 281: L369-L376.
26. Li D, Zhou N, Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol 1999; 277: L841-L847.
27. Schermuly R, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
28. YoshinaS,TanakaA,Kuo SC.[Studies on heterocyclic compounds. XXXIV. Synthesis of furo[3,2-c]pyrazole derivatives. 2) Electrophilic substitution of 1,3-diphenylfuro[3,2-c]pyrazole]. Yakugaku Zasshi 1978; 98: 204-209.
29. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84: 4226-4233.
30. Hoenicka M, Becker EM, Apeler H, et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med 1999; 77: 14-23.
31. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide- sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 1997; 120: 681-689.
32. Schmidt K, Schrammel A, Koesling D, Mayer B. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol Pharmacol 2001; 59: 220-224.
33. Galle J, Zabel U, Hubner U, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999; 127: 195-203.
34. Stasch JP, Alonso-Alija C, Apeler H, et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002; 135: 333-343.
35. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-215.
36. Straub A, Stasch JP, Alonso-Alija C, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001; 11: 781-784.
37. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-768.
38. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006; 90: 135-144.
39. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289:L798-L806.
40. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-295.
41. Evgenov OV, Ichinose F, Evgenov NV, et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004; 110: 2253-2259.
42. Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007; 176: 1-8.
43. Ghofrani HA, Grimminger F. Modulating cGMP to treat lung diseases. Handb Exp Pharmacol 2009; 191: 469-483.
44. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, tolerability and safety of the soluble guanylate cyclase stimulator BAY 632521; an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48: 926-934.
45. s 45 Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J2009; [Epub ahead of print PMID: 19129292].
46. Ghofrani HA, Weimann G, Frey R, et al. BAY 63-2521, anoral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology 2007; 7: S8.
47. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
48. Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. Eur Respir Rev 2009; 18: 24-28.